BofA notes that Merck shares have been volatile as investors have contemplated various scenarios regarding the approval of sotatercept and its language, including “a lot of investor angst” given the
BofA notes that Merck shares have been volatile as investors have contemplated various scenarios regarding the approval of sotatercept and its language, including “a lot of investor angst” given the
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK – Research Report), Shockwave Medical (SWAV – Research Report) and Korro Bio (KRRO – Research Report) with bullish sentiments.
Merck & Company (MRK)
TD Cowen analyst Steve Scala maintained a Buy rating on Merck & Company today and set a price target of $135.00. The company’s shares closed last Tuesday at $125.52, close to its 52-week high of $130.24.
According to TipRanks.com, Scala is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merck & Company with a $134.59 average price target, a 7.0% upside from current levels. In a report issued on March 18, Bank of America Securities also maintained a Buy rating on the stock with a $135.00 price target.
See today’s best-performing stocks on TipRanks >>
Shockwave Medical (SWAV)
Piper Sandler analyst Adam Maeder maintained a Buy rating on Shockwave Medical today and set a price target of $290.00. The company’s shares closed last Tuesday at $316.07, close to its 52-week high of $327.73.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
Currently, the analyst consensus on Shockwave Medical is a Moderate Buy with an average price target of $253.29, representing a -12.0% downside. In a report issued on March 19, Bank of America Securities also reiterated a Buy rating on the stock with a $310.00 price target.
Korro Bio (KRRO)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio today and set a price target of $180.00. The company’s shares closed last Tuesday at $86.95, close to its 52-week high of $89.00.
According to TipRanks.com, Rahimi is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Korro Bio with a $122.50 average price target, which is a 67.6% upside from current levels. In a report issued on March 12, RBC Capital also maintained a Buy rating on the stock with a $70.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRK:
Wells Fargo raised the firm’s price target on Merck to $135 from $130 and keeps an Equal Weight rating on the shares. The firm notes WINREVAIR, or sotatercept, was approved
Wells Fargo העלו את מחיר היעד שלהם עבור Merck ל-135 ליש”ט מהמחיר הקודם של 130 ליש”ט וממשיכים להמליץ על החזקת המניות. הם מציינים כי WINREVAIR, הידוע גם כסוטטרספט, קיבל אישור
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $135.00. Mohit Bansal has given his